immune astrocytopathy with glial fibrillary acidic protein (GFAP-IgG) as a biomarker may include myelitis sometimes longitudinally extensive as a component of a meningoencephalomyelitis. 3 We present additional serological data with regard to 2 novel glial targets (MOG and GFAP) in patients with rLETM. i Long-term monoclonal antibodies included ocrelizumab and alemtuzumab.
j An EDSS score of 6 indicates that the patient requires intermittent or unilateral assistance (cane, crutches, or braces) to walk 100 m with or without resting. An EDSS score of 8 indicates that the patient is restricted to bed or chair or perambulated in a wheelchair but may be out of bed much of the day, retains many self-care functions, and generally has effective use of his or her arms.
Methods | We conducted a cohort study investigating MOG-IgG and GFAP-IgG serostatus in patients with rLETM. Adult (age, ≥16 years) patients fulfilling the following criteria were included: (1) 2 or more radiologically confirmed consecutive episodes of LETM (≥3 contiguous vertebral segments in length); (2) infectious, rheumatologic, vascular, and neoplastic causes excluded after a variety of serological, microbiological, and radiological tests were performed as deemed clinically appropriate; and (3) serum available. The study protocol was reviewed and approved by the Mayo Clinic institutional review board. Patients provided written consent for passive use of their medical records for research purposes.
Patients from the 2014 study, 1 2005 to 2011, for whom serum samples were available (n = 41) were included; 29 patients identified from 2011 to 2017 were added. These patients were identified through the Mayo Clinic medical records database using the search terms LETM and recurrent LETM. For compari- Indirect immunofluorescence assay was used to screen for GFAP-IgG. 6 Frequency of glial autoantibody detection was determined and compared in the different LETM phenotypes; 50 healthy individuals and 50 patients with multiple sclerosis (MS) served as control patients.
Results | We identified 70 consecutive patients with rLETM and 81 with sLETM, grouped by phenotype (Table) : (1) For the total rLETM cohort, AQP4-IgG was detected in 65 of 70 patients (93%) and MOG-IgG1 was detected in only 1 of 57 patients (2%) who subsequently developed optic neuritis. The frequency of AQP4-IgG was significantly higher than MOG-IgG (P < .001, Figure, A and C).
For rLETM alone, no patient was MOG-IgG1 positive. Of 11 rLETM+ patients, 10 (91%) were AQP4-IgG positive and 1 patient (9%) was MOG-IgG1 positive ( Figure, A and B) .
For sLETM alone, the frequency of AQP4-IgG was 28 of 57 patients (49%) and of MOG-IgG1 was 3 of 39 patients (8%). For sLETM+, the frequency of AQP4-IgG was 12 of 24 patients (50%) and of MOG-IgG1 was 4 of 18 patients (22%).
None of the patients (including 62 with cerebrospinal fluid samples) tested positive for GFAP-IgG. None of the 50 healthy controls and 50 patients with MS tested positive for MOG, AQP4, or GFAP-IgG.
Discussion | This study, the first to our knowledge to investigate MOG-IgG1 serostatus in patients with rLETM, reports that autoimmune MOG-opathy can present with LETM, but recurrent sequential LETM is uncommon among patients with MOG-IgG (Figure, C) . The single patient with rLETM and MOG-IgG1 subsequently developed optic neuritis.
The 15% (7 of 47) frequency of MOG-IgG1 in sLETM patients in this study is similar to that reported by Cobo-Calvo and colleagues 2 (MOG-IgG1 in 13 of 56 patients [23%]). The lack of patients with sLETM or rLETM who were seropositive for GFAP-IgG suggests that isolated LETM does not fall within the autoimmune GFAP astrocytopathy spectrum. Accepting potential confounding by referral bias, autoimmune AQP4 channelopathy is the cause of half of sLETM cases and 93% of rLETM cases.
